Floatz logo

Dichloroacetate

MELAS Syndrome

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MELAS Syndrome cohort.

Asset / SponsorPhaseRating
Sonlicromanol
Khondrion BV
Phase 3BB
Fluzone
Stanford University
Phase 4BB
Idebenone
Michio Hirano
Phase 2B
ARG
The Hospital for Sick Children
Phase 2B
Zagociguat
Tisento Therapeutics
Phase 2CCC

View all 10 →

Same molecule, other indications

Dichloroacetate is also rated in:

glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
49 / 100
View asset →
lung cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →